Reviews/GLP-1 Receptor Agonists/Improve breast cancer disease-free survival
Cancer · GLP1-CAN-05 · v2
The claim asks whether these weight-loss and diabetes drugs help breast cancer survivors with obesity avoid cancer coming back or stay disease-free. The studies that actually measured this exact outcome mostly found no difference: the largest survivor cohort saw no change in disease-free survival [15], and two others found recurrence rates and recurrence risks that were not statistically different [6],[9]. The one study reporting a benefit on a related outcome was about in-situ breast lesions progressing to invasive disease, not recurrence in obese survivors [14]. Several studies did report that patients on these drugs lived longer overall [17],[18],[19], but longer overall survival is a different thing from avoiding cancer recurrence, and these drugs are already known to reduce heart and metabolic deaths. Because the evidence aimed squarely at recurrence and disease-free survival was repeatedly null, the panel treated the claim as unsupported as worded.
Four papers directly measure the claim's endpoint, and the direct signal is overwhelmingly null: [15] reports no DFS difference in 1,022 survivors, [6] reports local, locoregional and distant recurrence rates that were not statistically significant, and [9] reports non-significant recurrence hazard ratios of 0.80 (95% CI 0.50-1.30) all-type and 0.60 (95% CI 0.31-1.17) in obesity-associated cancers. The only on-endpoint positive, [14], is progression of DCIS to invasive and metastatic disease (HR 0.36, 95% CI 0.29-0.44), not recurrence in obese survivors. Where benefit appears, it is overall or all-cause mortality: 2-year OS in metastatic ER+ disease [17], overall mortality (HR 0.34) in diabetic breast cancer [18], and all-cause mortality (RR 0.41 and 0.60) in obese patients on endocrine therapy [19]. A contrary signal exists in incidence, where [12] links GLP-1 RA use to higher breast cancer incidence in type 2 diabetes. The contested point: The division is endpoint, not direction: the mortality studies [17],[18],[19] show a consistent survival benefit, while the DFS/recurrence studies [15],[6],[9] show nothing. Whether the mortality benefit can stand in for the claim's recurrence/DFS endpoint is exactly what separates a supportive reading from the null one, and the panel treated the two endpoints as distinct because GLP-1 RAs act on cardiometabolic mortality independent of cancer.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Endpoint substitution: every benefit signal ([17],[18],[19]) is overall or all-cause mortality, not DFS/recurrence; GLP-1 RAs reduce cardiometabolic mortality independent of cancer, so a mortality benefit cannot be read as the claim's DFS/recurrence benefit.
The claim's exact endpoint is directly null: [15] reports no DFS difference, [6] non-significant recurrence, and [9] non-significant recurrence HRs — three on-endpoint nulls.
Where it remains uncertain. Overall and all-cause mortality benefits are reported [17],[18],[19], but these are a different endpoint from DFS/recurrence and GLP-1 RAs reduce cardiometabolic death independent of cancer.
Aleatory
Only 70 of 5,430 patients were GLP-1 RA treated in [6] and recurrence HRs in [9] span 1 (0.50-1.30), so small event counts leave the recurrence estimate dominated by chance.
Epistemic
Every human source is retrospective; authors in [4],[6],[15],[17],[18] repeatedly state trials are warranted or needed, so the causal question is unresolved.
Inferential
The benefit evidence [17],[18],[19] is overall/all-cause mortality; inferring a DFS/recurrence benefit from it assumes the effect runs through cancer control rather than cardiometabolic pathways.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Directly measures recurrence in overweight/obese early BC: no significant reduction.
“Rates of local, locoregional, and distant breast cancer recurrence were 1.5%, 0%, 1.5% in the S/T treated patients and 1.3%, 4.7% and 3.3% in the untreated patients. None of these differences were statistically significant.”
Panel auditInternal validity: low · scope of inference: Whether GLP-1 agonist use is associated with recurrence in overweight/obese early breast cancer patients.Key limitations: tiny treated arm (n=70) · unadjusted recurrence comparison · underpowered for recurrence
Large survivor cohort: recurrence association non-significant (CIs span 1), including the obesity-associated subgroup.
“ever use of GLP-1 RAs was not significantly associated with cancer recurrence among all-type cancer survivors (HR, 0.80; 95% CI, 0.50-1.30) or obesity-associated cancer survivors (HR, 0.60; 95% CI, 0.31-1.17)”
Panel auditInternal validity: medium · scope of inference: Association of GLP-1 RA use with recurrence and mortality across cancer survivors.Key limitations: not breast-specific · recurrence ascertainment uncertain · obesity subgroup is mixed cancers
Only on-endpoint positive, but it is DCIS progression to invasive/metastatic disease, not recurrence in obese survivors, and not obesity-restricted.
Panel auditInternal validity: medium · scope of inference: Progression and survival in DCIS patients on hormonal therapy with GLP-1 agonist use.Key limitations: DCIS not invasive survivors · obesity not specified · retrospective EHR confounding
The endpoint is overall survival in metastatic disease, not disease-free survival or recurrence in obese survivors.
Panel auditInternal validity: medium · scope of inference: Overall survival and adverse events in ER+ metastatic breast cancer with GLP-1a use.Key limitations: metastatic not survivors · OS not DFS/recurrence · obesity not isolated
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The best-matched direct DFS/recurrence evidence is consistently null and the supportive signals are on a different endpoint, so the claim as worded leans unsupported.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised DFS/recurrence trial. The claim's endpoint has only retrospective, mostly abstract-level evidence, so causality cannot be established and confounding cannot be excluded. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial of GLP-1 RA versus placebo in obese breast cancer survivors with DFS and recurrence as pre-specified primary endpoints.
Open question: Do GLP-1 receptor agonists reduce breast cancer recurrence or improve disease-free survival specifically in obese survivors? Why it is still open: The only DFS study [15] was null, the recurrence studies [6],[9] were non-significant with wide intervals, and none was restricted to obese survivors on this endpoint.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19